Navidea Biopharmaceuticals Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Navidea Biopharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Navidea Biopharmaceuticals stock.
View analyst ratings for Navidea Biopharmaceuticals or view top-rated stocks.

Wall Street analysts have given Navidea Biopharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Navidea Biopharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Navidea Biopharmaceuticals saw a drop in short interest during the month of February. As of February 12th, there was short interest totaling 166,200 shares, a drop of 33.0% from the January 28th total of 248,100 shares. Based on an average daily volume of 305,700 shares, the short-interest ratio is presently 0.5 days.
View Navidea Biopharmaceuticals' Short Interest.

Navidea Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Navidea Biopharmaceuticals.

Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) posted its quarterly earnings data on Thursday, November, 12th. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.04. The biopharmaceutical company had revenue of $0.27 million for the quarter, compared to analysts' expectations of $0.30 million. Navidea Biopharmaceuticals had a negative net margin of 1,310.93% and a negative trailing twelve-month return on equity of 372.59%.
View Navidea Biopharmaceuticals' earnings history.

Navidea Biopharmaceuticals' stock was trading at $0.96 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NAVB stock has increased by 126.0% and is now trading at $2.17.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued 12 month target prices for Navidea Biopharmaceuticals' stock. Their forecasts range from $7.00 to $8.00. On average, they anticipate Navidea Biopharmaceuticals' share price to reach $7.50 in the next year. This suggests a possible upside of 245.6% from the stock's current price.
View analysts' price targets for Navidea Biopharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Navidea Biopharmaceuticals include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Insulet (PODD) and Varian Medical Systems (VAR).
View all of NAVB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include OPKO Health (OPK), Ampio Pharmaceuticals (AMPE), CorMedix (CRMD), Catalyst Pharmaceuticals (CPRX), FuelCell Energy (FCEL), Palatin Technologies (PTN), Trevena (TRVN), Agenus (AGEN), Dynavax Technologies (DVAX) and Genocea Biosciences (GNCA).

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

Navidea Biopharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.21%), Allred Capital Management LLC (0.20%) and HighTower Advisors LLC (0.14%). Company insiders that own Navidea Biopharmaceuticals stock include Claudine Bruck, Jed Latkin, John K Jr Scott, Malcolm G Witter and Sarah Kathryn Rouan.
View institutional ownership trends for Navidea Biopharmaceuticals.

NAVB stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Allred Capital Management LLC.
View insider buying and selling activity for Navidea Biopharmaceuticals or view top insider-selling stocks.

NAVB stock was acquired by a variety of institutional investors in the last quarter, including HighTower Advisors LLC. Company insiders that have bought Navidea Biopharmaceuticals stock in the last two years include Claudine Bruck, Jed Latkin, John K Jr Scott, Malcolm G Witter, and Sarah Kathryn Rouan.
View insider buying and selling activity for Navidea Biopharmaceuticals or or view top insider-buying stocks.

Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NAVB stock can currently be purchased for approximately $2.17.

Navidea Biopharmaceuticals has a market capitalization of $60.73 million and generates $660,000.00 in revenue each year. The biopharmaceutical company earns $-10,950,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.

Navidea Biopharmaceuticals employs 13 workers across the globe.

The official website for Navidea Biopharmaceuticals is www.navidea.com.

Navidea Biopharmaceuticals is headquartered at 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States.

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500 or via email at [email protected]